KMANPUB | Health Nexus Vol. 2 No. 1 (2024): 43-56

Article history:
Received 19 September 2023
Revised 07 November 2023
Accepted 12 November 2023
Published online 01 January 2024

Advances in Radiological Techniques for Cancer Diagnosis: A Narrative Review of Current Technologies

Zuhair Ali[1*], Anas Hamdoun[2], Abdelmoneim Alattaya[3]

[1] Antrim Area Hospital Antrim, County Antrim, Ireland
[2] King Abdullah bin Abdulaziz University Hospital, Riyadh, KSA
[3] John Hopkins Aramco Healthcare, Dhahran, KSA

*** Corresponding author email address**: Zuhair71@hotmail.com

A r t i c l e I n f o

Article type:
Review Article

How to cite this article:
Ali, Z., Hamdoun, A., & Alattaya, A. (2024). Advances in Radiological Techniques for Cancer Diagnosis: A Narrative Review of Current Technologies. *Health Nexus, 2*(1), 43-56.
https://doi.org/10.61838/kman.hn.2.1.6

A B S T R A C T

This review aimed to assess the recent advancements in radiological techniques for cancer diagnosis, focusing on the clinical applications and the potential for these technologies to improve patient experiences and personalize the diagnostic process. A detailed literature search was conducted in several databases up to February 2024, using a combination of keywords and Medical Subject Headings (MeSH) terms related to "cancer diagnosis" and "radiological techniques." The inclusion criteria were peer-reviewed articles in English that focus on advanced imaging modalities in cancer diagnosis. Data were synthesized to identify key advancements, challenges, and future directions. The advancements in photon counting detector Computed Tomography (CT), quantitative imaging biomarkers, and emerging diagnostic substances like radiotracers were highlighted. The review identified significant improvements in imaging techniques such as multiparametric Magnetic Resonance Imaging (MRI) and diffusion-weighted imaging. It also addressed the clinical, technological, and economic challenges in adopting these advancements globally, as well as the initiatives aimed at improving access to advanced diagnostics. The importance of collaboration between radiologists, oncologists, and engineers in optimizing these technologies for clinical use was emphasized. Radiological advancements have enhanced the capacity for precise and personalized cancer diagnosis, with a significant positive impact on patient care. Despite the promising developments, challenges related to access and implementation persist. Addressing these issues requires global efforts to ensure equitable access to advanced diagnostics and collaborative innovation to refine and integrate these technologies into clinical practice, ultimately leading to better global health outcomes.

Keywords: *Biomarker Imaging, Biopsy Techniques, Contrast Imaging, Functional Imaging, Imaging Advances, Neoplastic Imaging, Oncology Modalities, Precision Oncology, Radiomics, Radiotracer Use, Screening Technology, Tumor Characterization.*

1. Introduction

Cancer is a major global health challenge, responsible for millions of deaths worldwide and placing a significant burden on individuals, families, and healthcare systems. According to the World Health Organization (WHO), cancer is one of the leading causes of death globally, accounting for approximately 10 million deaths annually (1). The impact of cancer extends beyond mortality, affecting the quality of life for individuals living with the disease and their caregivers (2). It poses physical, emotional, and financial challenges (2). Early detection and effective diagnostic strategies are crucial in improving cancer outcomes. Timely intervention when the disease is more treatable can significantly impact survival rates (2). Advanced imaging modalities and molecular diagnostics play a key role in early detection, accurate diagnosis, and staging of cancer (3). These techniques provide valuable information about tumor size, location, and potential metastases, aiding in treatment planning and decision-making (3).

Radiological advancements offer an ideal method for enhancing cancer diagnoses. Radiology plays a crucial role in cancer detection, staging, and treatment planning (4). Traditional radiological techniques, such as X-rays, computed tomography (CT), and magnetic resonance imaging (MRI), have been excellent tools in visualizing anatomical structures and detecting tumors (4, 5). However, recent developments in radiological techniques have expanded the abilities and precision of cancer diagnostics (2). One significant advancement is the advent of functional imaging modalities, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) (6). These methods offer an understanding into the metabolic and molecular processes of tumors, allowing for the detection of regions exhibiting irregular cellular activities (6). PET, in particular, utilizes radiotracers that selectively accumulate in cancer cells, allowing for the detection of small lesions and the assessment of tumor aggressiveness (6).

Another notable advancement is the integration of advanced imaging technologies, such as multiparametric MRIs and diffusion-weighted imaging (DWI) (7). These techniques provide detailed information about tissue characteristics, microstructural changes, and blood flow patterns, aiding in the differentiation between malignant and benign lesions (7). Additionally, functional MRIs techniques, such as dynamic contrast-enhanced MRIs (DCE-MRI) and magnetic resonance spectroscopy (MRS), offer a comprehensive understanding into tumor vascularity and metabolic alterations, respectively (8). Furthermore, the development of hybrid imaging systems, such as PET-CT and PET-MRI, has revolutionized cancer diagnostics by combining functional and anatomical information in a single examination (9). These hybrid systems offer improved sensitivity and specificity, enabling more accurate tumor localization, staging, and treatment response assessment (9). Advancements in radiological techniques also include the utilization of artificial intelligence (AI) and machine learning algorithms (10). AI-based approaches have shown promise in automating image analysis, improving lesion detection, and aiding in radiological interpretation (10). These technologies can assist radiologists in making more accurate and efficient diagnoses, particularly in complex cases or when dealing with large volumes of imaging data (10).

Based on the observed gaps in the comprehensive comparison of the efficacy and specificity of advanced radiological techniques against traditional methods across various cancer types, and the underexplored integration of artificial intelligence in enhancing diagnostic accuracy and patient outcomes in oncology, the aim of this study was to review the recent advancements in radiological techniques for cancer diagnosis. Specifically, this review seeks to clarify the comparative effectiveness and utility of emerging imaging modalities and provide a critical analysis of their implications for clinical practice and patient care.

2. Methods and Materials

This narrative review explored the recent advancements in radiological techniques in cancer diagnosis. Our literature search aimed to identify, evaluate, and synthesize findings from a range of sources to provide an in-depth understanding of the current state of the art and its implications for clinical practice.

2.1. Search Strategy

We conducted a detailed search of electronic databases including PubMed, Scopus, Web of Science, and IEEE Xplore for studies published from January 2013 to February 2024. To ensure a broad and inclusive retrieval of relevant literature, we used a combination of keywords and Medical Subject Headings (MeSH) terms related to "cancer diagnosis," "radiological techniques," "advanced imaging modalities," "artificial intelligence," and "machine

Health Nexus
E-ISSN: 2981-2569

learning." Boolean operators (AND, OR) were employed to combine these terms in various configurations to optimize the search. For example, our search strings included combinations such as "cancer diagnosis AND radiological techniques," "advanced imaging modalities OR radiology AND cancer," and "artificial intelligence OR machine learning AND cancer diagnosis."

2.2. Inclusion and Exclusion Criteria

Studies were selected based on the following inclusion criteria: (1) articles published in English, (2) studies focusing on the application of radiological techniques in cancer diagnosis, and (3) articles that investigated the efficacy, specificity, challenges, and clinical integration of these technologies. Exclusion criteria included non-peer-reviewed articles, studies not related to cancer diagnosis, and articles focusing solely on treatment outcomes without a diagnostic component.

2.3. Data Extraction and Synthesis

Key information was extracted from each article, including study design, objectives, methodologies, key findings, and conclusions. This information reinforced our review's structure, directly informing the development of our plan. Our literature search revealed key topics and gaps in current knowledge, which influenced the structure of our review as follows:

- Traditional Diagnostic Methods and Their Limitations
- Advancements in Imaging Techniques
  - Conventional Imaging Modalities
  - Emerging Imaging Technologies
  - Role of Diagnostic Substances
  - Molecular, Metabolic, Genomic, and Proteomic Imaging
  - Integration of AI with Traditional Modalities
- Patient-Centered Approaches
- Global Access and Disparities
- Regulatory and Approval Processes
- *Collaboration Between Disciplines*
- *Challenges and Future Directions*

3. Traditional Diagnostic Methods and Their Limitations

Conventional diagnostic methods, including physical exams, laboratory testing, and imaging technologies like X-rays, CT scans, and MRIs, play a pivotal role in cancer detection and treatment planning (5). However, these traditional approaches have limitations. Physical exams can only detect surface abnormalities, missing internal or small cancers (5). Laboratory tests, while monitoring specific biomarkers, often lack the specificity for a definitive cancer diagnosis, leading to potential misinterpretations (11). Similarly, standard imaging techniques, despite their utility in visualizing anatomical structures, struggle to distinguish between benign and malignant tumors accurately, particularly in early cancer stages (2, 11). This inadequacy emphasises the necessity for advanced diagnostic techniques capable of enhancing detection accuracy, refining disease staging, and facilitating personalized treatment plans (2). The heterogeneity of cancer types, each with unique characteristics, challenges conventional diagnostics (12). Generic methods like physical exams and laboratory tests fail to capture the subtle distinctions among various malignancies (12). Although conventional imaging provides valuable understanding on the tumor location and size, it frequently falls short in detecting minor cancer spread or accurately assessing tumor margins (12). The critical need for diagnostics offering comprehensive visualization and genetic profiling of tumors is evident. For a detailed comparison of the advantages and limitations of traditional imaging modalities versus advanced imaging techniques in oncology, refer to Table 1.

Health Nexus
E-ISSN: 2981-2569

Table 1

Advantages and limitations of traditional imaging modalities compared to advanced imaging techniques in oncology

Imaging Modality	Advantages	Limitations	Clinical Applications
X-rays (13)	Widely available and cost-effective. Useful for detecting bony abnormalities and calcifications. Rapid imaging acquisition allows for quick assessment in emergency settings.	Limited soft tissue contrast Often insufficient for detecting early-stage tumors or subtle abnormalities. Ionizing radiation exposure poses potential risks, particularly in frequent or pediatric imaging.	Skeletal imaging for bone fractures and lesions. Dental imaging for caries detection and root canal assessment. Chest X-rays for pulmonary conditions such as pneumonia or lung cancer.
Computed Tomography (CT) (14)	High spatial resolution enables detailed anatomical visualization. Rapid scan times facilitate imaging of moving structures, such as the heart or lungs. Versatile imaging modality suitable for various body regions and pathologies.	Ionizing radiation exposure, although reduced with modern techniques, remains a concern, especially in cumulative or pediatric imaging. Limited soft tissue contrast compared to MRI, impacting sensitivity for certain tumor types. Contrast agent administration may pose risks, particularly in patients with renal impairment or allergies.	Trauma imaging for assessing internal injuries and hemorrhages. Oncological staging for tumor localization, extent evaluation, and treatment planning. Vascular imaging for detecting aneurysms, stenoses, or thromboses.
Magnetic Resonance Imaging (MRI) (15)	Excellent soft tissue contrast allows for superior delineation of tumor margins and surrounding structures. Multiplanar imaging capabilities provide comprehensive anatomical assessment. No ionizing radiation exposure, making it safe for repeated imaging and pediatric patients.	Longer acquisition times compared to CT may result in motion artifacts or patient discomfort. High cost and limited availability in certain healthcare settings may restrict access to MRI imaging. Contraindications such as metallic implants or claustrophobia may limit patient suitability for MRI scans.	Brain imaging for tumor characterization and neurodegenerative diseases. Breast imaging for detecting and characterizing breast lesions. Musculoskeletal imaging for evaluating joint pathology and soft tissue tumors.
Ultrasound (16)	Non-invasive and widely available imaging modality with no ionizing radiation exposure. Real-time imaging capability allows for dynamic assessment of moving structures, such as blood flow or fetal development. Portable and cost-effective, suitable for bedside or point-of-care imaging.	Operator-dependent technique, with image quality influenced by operator skill and patient factors. Limited penetration and resolution in obese or deep-seated structures may hinder visualization of certain tumors or anatomical details. Suboptimal visualization of structures behind gas-filled organs or bones, limiting imaging in these regions.	Obstetric imaging for fetal monitoring and anomaly detection. Abdominal imaging for evaluating liver, gallbladder, and renal pathology. Vascular imaging for assessing blood flow and detecting deep vein thrombosis.
Nuclear Medicine (PET/SPECT) (17)	Functional imaging modalities provide insights into metabolic and molecular processes within tumors. High sensitivity for detecting small lesions and assessing treatment response. PET/CT and SPECT/CT hybrid imaging combine functional and anatomical information for more accurate localization and staging.	Limited anatomical detail compared to CT or MRI, requiring correlation with other imaging modalities for precise localization. Radiotracer availability and decay limitations may restrict imaging scheduling and timing. Radiation exposure associated with radiotracer administration, although typically lower than conventional CT scans.	Oncological imaging for tumor detection, staging, and treatment response assessment. Neurological imaging for evaluating brain function and neurodegenerative diseases. Cardiac imaging for myocardial perfusion assessment and viability testing.

CT: Computed Tomography, MRI: Magnetic Resonance Imaging, PET: Positron Emission Tomography, SPECT: Single Photon Emission Computed Tomography

4. Advancements in Imaging Techniques

Conventional Imaging Modalities: Evolution and Current State in Oncology

The evolution of conventional imaging modalities has had a profound impact on the field of oncology, offering clinicians a range of tools for the diagnosis, staging, and monitoring of cancer (18, 19). As these modalities have advanced, they have provided increasingly sophisticated ways to visualize tumors, understand their behavior, and guide treatment (18-20).

X-ray Imaging has transitioned from simple two-dimensional imaging to digital mammography, which has significantly improved the detection of breast cancer, particularly in its early stages (21). The ability to detect microcalcifications and subtle changes in breast tissue

Health Nexus
E-ISSN: 2981-2569

density has made mammography an indispensable screening tool in oncology (21).

Computed Tomography (CT) scans have become more refined, offering high-resolution images that are invaluable in the detection and staging of various cancers. The development of multi-slice CT has enabled detailed cross-sectional views of the body, allowing for the precise localization of tumors and assessment of metastatic spread (2, 22). With the aid of contrast agents, CT scans can also provide information about the vascular supply to tumors, which is crucial for planning treatments such as surgery or radiotherapy (22).

Magnetic Resonance Imaging (MRI) has seen enhancements in its ability to differentiate between tissue types, making it particularly useful for brain, spinal, and musculoskeletal cancers (15, 23). High-resolution images with contrast detail offer a clearer picture of tumor margins, which is critical for surgical planning (15, 24). Advanced MRIs techniques, such as functional MRIs and whole-body diffusion-weighted imaging, are now being used to assess tumor biology and response to treatment (24).

Ultrasound has evolved with higher resolution and Doppler capabilities, allowing for the non-invasive assessment of soft-tissue tumors and the evaluation of blood flow in cancerous tissues (16). Ultrasound-guided biopsies have become a routine procedure in diagnosing various cancers, providing a minimally invasive option to obtain tissue samples (16).

The evolution of these imaging modalities has been guided by the need for greater accuracy and specificity in cancer detection, as well as the requirement to reduce exposure to radiation and invasive procedures (25). As a result, these traditional modalities have not only improved in their imaging capabilities but also in their safety and utility in oncology. Each of these modalities plays a unique role in the management of cancer, and their continuous improvement has significantly enhanced the clinician's ability to provide personalized cancer care (25). The ongoing advancements in conventional imaging modalities hold promise for even more precise cancer diagnosis, better treatment outcomes, and improved patient quality of life (25).

4.1. Emerging Imaging Technologies: Advancements in Oncological Diagnostics

The field of oncology has greatly benefited from the advancements in emerging imaging technologies, which offer enhanced sensitivity and specificity in the diagnosis and characterization of cancers (26). Technologies such as Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), multiparametric Magnetic Resonance Imaging (mpMRI), and Diffusion-Weighted Imaging (DWI) have provided new opportunities for detecting diseases early, accurately determining the extent of the disease, and monitoring how well treatments are working (26, 27). Table 2 provides a detailed overview of each technology's capabilities and applications in oncology.

Positron Emission Tomography (PET) has become a cornerstone in oncology for its ability to detect metabolically active tumors (27). The development of cancer-specific tracers has improved the specificity of PET imaging, allowing for targeted imaging of various cancer types. Functional imaging with PET is essential for assessing cancer metabolism, tracking therapy effectiveness, and identifying cancer recurrence, therefore playing a critical role in tailoring treatment for cancer patients (27).

Single Photon Emission Computed Tomography (SPECT), while similar to PET in its functional approach, uses different radiotracers and provides complementary information (28). Advancements in SPECT technology, including hybrid SPECT/CT systems, have improved the anatomic localization of tumors (28). SPECT's ability to assess regional tumor biology and heterogeneity is particularly useful in personalized treatment planning and dose optimization in radionuclide therapy (28).

Multiparametric MRIs (mpMRI) is an advanced imaging approach that integrates anatomical, functional, and molecular imaging (29). It has demonstrated potential in identifying and determining the extent of prostate cancer, breast cancer, and liver cancers. mpMRI combines different MRI sequences to offer a thorough examination of the tumor environment, encompassing its blood supply, cell density, and chemical alterations (29). This multifaceted strategy is crucial for differentiating between non-cancerous and cancerous tissues and evaluating the severity of malignancies (29).

Diffusion-Weighted Imaging (DWI) is an MRIs technique that measures the diffusion of water molecules within tissue and is particularly sensitive to tissue density and cellularity (30). DWI has become a powerful tool in oncology for its ability to distinguish between cancerous and normal tissues without the need for contrast agents (30). It is especially useful in the early detection of primary

Health Nexus
E-ISSN: 2981-2569

and metastatic brain tumors, as well as in the assessment of treatment response in other cancer types (30).

These emerging imaging technologies are continually refined through the integration of AI, enhancing image quality, and quantification (20, 21, 30). The ability of these modalities to provide a non-invasive insight into the molecular and functional aspects of cancer makes them indispensable in the era of precision oncology (30). The advancements in PET, SPECT, mpMRI, and DWI represent a transformative shift in the oncological imaging landscape (30). They enable clinicians to visualize cancer in unprecedented detail and offer a more nuanced understanding of tumor biology, which is critical for advancing personalized cancer care and improving patient outcomes.

Table 2

Comparison of Diagnostic Substances Used in PET and MRI Imaging.

Diagnostic Substance	PET Imaging	MRI Imaging
Fluorodeoxyglucose (FDG) (31)	Radiotracer used to assess glucose metabolism in tissues. Widely employed in oncology for detecting various cancers. Particularly useful for visualizing hypermetabolic lesions indicative of malignancy.	Contrast agent used to enhance signal intensity in MRI scans. Primarily utilized for anatomical imaging and functional assessment. Limited role in direct cancer detection but may aid in characterizing tumor vascularity or blood-brain barrier disruption.
Prostate-Specific Membrane Antigen (PSMA) (32)	Radiolabeled ligand targeting PSMA, a transmembrane protein overexpressed in prostate cancer cells. Enables highly specific detection of prostate cancer lesions, including primary tumors and metastases. Enhances sensitivity and accuracy in prostate cancer staging and therapeutic monitoring.	Targeted imaging agent for detecting PSMA expression in prostate cancer. Offers improved visualization of primary and metastatic lesions compared to conventional MRI techniques. Facilitates precise localization and characterization of prostate cancer foci for treatment planning and monitoring.
18F-Fluciclovine (Axumin) (33)	Radiotracer targeting amino acid transport, particularly elevated in prostate cancer cells. Enables detection of recurrent prostate cancer in post-treatment settings, including local recurrence and distant metastases. Enhances diagnostic accuracy and guides salvage therapy decisions in patients with biochemical recurrence.	PET imaging agent used to detect sites of increased amino acid metabolism, indicative of prostate cancer recurrence. Provides superior sensitivity and specificity compared to conventional imaging modalities for detecting small lesions and guiding targeted biopsy or therapy selection.
Gadolinium-based Contrast Agents (34)	Intravenous contrast agents used to enhance signal intensity in MRI scans, aiding in tissue characterization and lesion detection. Offer superior soft tissue contrast and spatial resolution compared to non-contrast MRI sequences. Widely employed in oncologic MRI for detecting and characterizing tumors, assessing treatment response, and monitoring disease progression.	Gadolinium-based contrast agents are widely used in MRI imaging for oncological applications. They enhance the contrast between tumor and normal tissue, aiding in the detection, characterization, and staging of malignancies. These agents are particularly useful in assessing tumor vascularity, blood-brain barrier integrity, and treatment response.

PET: Positron Emission Tomography, MRI: Magnetic Resonance Imaging

4.2. Role of Diagnostic Substances: Utilization of Contrast Agents and Radiotracers in Oncology

Diagnostic substances, including contrast agents and radiotracers, are crucial in enhancing imaging modalities (35). They significantly improve tumor visualization, offer valuable functional insights into cancerous tissues, and aid in the precise staging and monitoring of the disease (35).

Contrast Agents are used extensively with CT and MRIs to outline anatomical structures and highlight abnormalities indicative of cancer (35). In CT, iodinated contrast agents enhance the density of blood vessels and tumors, aiding in the detection and characterization of oncological lesions (36). Gadolinium-based agents in MRIs improve the visibility of tumors by altering the magnetic properties of the tissue, providing excellent soft tissue contrast crucial for detecting and staging cancer, as outlined in Table 3.

Radiotracers in PET imaging has revolutionized the detection and assessment of cancer by allowing for the visualization of metabolic processes (37). FDG is widely used in PET scans due to its effectiveness in highlighting areas of high glucose metabolism, a common characteristic

Health Nexus
E-ISSN: 2981-2569

of cancer cells (37). The introduction of more specialized tracers, such as those targeting PSMA in prostate cancer, has further improved the specificity of PET scans for certain cancers, which is particularly beneficial for early detection and treatment monitoring. The use of such diagnostic substances is extensively detailed in Table 3, providing an understanding on their function and clinical applications.

Hybrid imaging techniques: The utilization of these substances has also led to the development of hybrid imaging techniques such as PET/CT and PET/MRI, which combine functional and anatomical imaging data for a more comprehensive oncological assessment (38). These techniques allow for better localization of the metabolic abnormalities detected by PET, enhancing the diagnostic process, as discussed in Table 3.

In addition to their diagnostic value, these substances are also pivotal in treatment planning (39). For instance, contrast-enhanced MRIs can guide the biopsy process, ensuring that the most representative area of the tumor is sampled (39). Similarly, PET imaging can assess the efficacy of therapies by measuring changes in the metabolic activity of tumors over time. The role of diagnostic substances in oncology extends beyond imaging to include theranostics, an emerging field that combines therapy and diagnostics (38, 39). Certain radiotracers can be used not only to diagnose cancer but also to deliver targeted radiotherapy to cancer cells, as further explored in Table 3. The utilization of contrast agents and radiotracers represents a significant advancement in cancer diagnostics, contributing to the early detection, accurate staging, and effective monitoring of various cancer types (39). As research continues, we anticipate the development of newer diagnostic substances with even greater specificity and sensitivity, further revolutionizing the field of oncological imaging (23, 39).

4.3. Molecular, Metabolic, Genomic, and Proteomic Imaging: Innovations in Cancer Diagnostics

Advancements in molecular, metabolic, genomic, and proteomic imaging have significantly improved cancer diagnosis (40). These technologies enable clinicians to observe and evaluate cancer at a cellular and molecular scale, offering insights that surpass the capabilities of conventional imaging methods.

Molecular Imaging involves the visualization of specific molecules in the body and is pivotal for the detection of cancer (40). It often utilizes imaging modalities such as PET and SPECT, combined with targeted radiotracers, to identify molecular changes associated with cancer (40). For example, the use of tracers that target cell surface receptors or other tumor-specific antigens enables the visualization of cancer spread and may also inform on the most effective therapeutic approach (40).

Metabolic Imaging, particularly through PET scans using FDG, has been instrumental in oncology for its ability to illuminate areas of high glucose consumption, a hallmark of many cancer cells (41). Metabolic imaging helps distinguish between benign and malignant lesions, evaluate cancer aggressiveness, and track therapy response by showing tissue metabolic activity (41). Table 3 outlines the precise uses and advantages of metabolic imaging in the field of oncology.

Genomic Imaging seeks to correlate imaging findings with genomic data, offering a non-invasive means to gather genomic information (42). This imaging subset is part of the growing field of radiogenomics, which holds promise for identifying genetic mutations based on imaging characteristics (42). By doing so, it could potentially predict patient prognosis and response to targeted therapies.

Proteomic Imaging is an emerging field that focuses on the study of the proteome as it pertains to cancer (43). Proteomic imaging seeks to improve the comprehension of cancer biology and facilitate the creation of new biomarkers for cancer detection and targeted therapy by pinpointing protein expressions and alterations in tumors (43).

These advanced imaging techniques are reshaping the landscape of cancer diagnostics by providing detailed insights into the molecular and cellular processes of cancer (43). This facilitates the early detection and accurate characterization of tumors and supports personalized medicine by enabling treatment to be tailored to the individual molecular profile of each patient's cancer (43). The integration of these imaging modalities into clinical practice represents a significant challenge, requiring specialized equipment and expertise (43, 44). However, the potential benefits they offer in terms of improved diagnostic precision and personalized treatment plans are substantial, emphasising the importance of continued research and development in this area (44).

E-ISSN: 2981-2569

Table 3

Diagnostic Substances and Their Role in Cancer Imaging

Diagnostic Substance	Imaging Modality	Function	Clinical Applications	Advantages	Disadvantages
Fluorodeoxyglucose (FDG) (31)	PET scans	Radiotracer that accumulates in metabolically active tissues, including tumors, due to increased glucose metabolism. Provides functional information about tumor activity.	Oncological imaging for detecting primary tumors, metastases, and assessing treatment response. Differentiating between benign and malignant lesions, aiding in cancer staging.	High sensitivity for detecting malignancies. Versatile applications across various cancer types.	Limited specificity, leading to false positives. Accumulation in inflammatory or infectious lesions.
Prostate-Specific Membrane Antigen (PSMA) (32)	PET scans	Targeted radiotracer that binds to PSMA receptors, highly expressed in prostate cancer cells. Enables specific visualization of prostate cancer lesions.	Prostate cancer imaging for primary tumor localization, lymph node staging, and detecting metastases. Assessing treatment response and disease recurrence in prostate cancer patients.	High specificity for prostate cancer detection. Accurate localization of primary and metastatic lesions.	Limited availability and higher cost compared to conventional PET tracers. Potential false negatives in PSMA-negative tumors.
Gadolinium-based Contrast Agents (44)	MRI	Intravenous contrast agents that enhance the visibility of blood vessels and areas with disrupted blood-brain barriers, such as tumors. Highlight areas of abnormal vascularity and leakage.	Brain imaging for detecting and characterizing brain tumors, vascular malformations, and inflammation. Assessing tumor vascularity and permeability in oncological imaging for treatment planning and monitoring.	Excellent tissue contrast enhancement for visualizing vascular structures and lesions. No radiation exposure, making it safe for repeated use in patients.	Risk of NSF in patients with impaired renal function. Potential allergic reactions and gadolinium retention in certain patient populations.
Iodinated Contrast Agents (45)	CT scans	Intravenous contrast agents that opacify blood vessels and enhance contrast between tissues with differing densities. Improve visualization of vascular structures and tumors with increased vascularity.	Abdominal imaging for detecting liver lesions, renal masses, and vascular abnormalities. Pulmonary imaging for evaluating pulmonary embolism, lung nodules, and bronchial lesions.	Rapid enhancement of vascular structures and lesions, allowing for dynamic imaging studies. Wide availability and familiarity in clinical practice.	Potential nephrotoxicity, especially in patients with pre-existing renal impairment. Radiation exposure associated with CT scans.
Ferumoxytol (46, 47)	MRI	Superparamagnetic iron oxide nanoparticle-based contrast agent that accumulates in tissues with macrophage activity, such as tumors and inflammatory lesions. Provides functional and molecular information about tissue composition.	Oncological imaging for detecting and characterizing liver lesions, lymph node metastases, and soft tissue tumors. Assessing tumor-associated inflammation and angiogenesis in cancer patients.	High relaxivity and prolonged blood pool enhancement, allowing for delayed imaging acquisitions. No risk of NSF compared to gadolinium-based agents.	Limited availability and off-label use, leading to potential regulatory constraints. Higher cost compared to conventional MRI contrast agents.

CT: Computed Tomography, MRI: Magnetic Resonance Imaging, NSF: Nephrogenic Systemic Fibrosis, PET: Positron Emission Tomography

4.4. Integration of AI with Traditional Modalities: Showcase AI's Impact in Oncology Through Case Studies and Recent Breakthroughs

The integration of Artificial Intelligence (AI) with traditional imaging modalities is forging a new frontier in cancer diagnostics (48). AI's ability to learn from large datasets and identify patterns has brought about a significant leap in the accuracy, efficiency, and predictive power of cancer detection and monitoring (48). For a comprehensive understanding of the clinical applications of emerging technologies in radiology, including those enhanced by AI, Table 4 offers an in-depth look at their implications for transforming oncological care.

AI in Mammography: In breast cancer screening, AI algorithms have been trained on thousands of mammograms to distinguish between benign and malignant lesions (49). Recent studies demonstrated that AI model outperformed experienced radiologists in reducing both false positives and false negatives, offering a promise of improved early detection rates which is critical for successful treatment outcomes (49).

AI in Radiomics: AI's use in radiomics involves extracting several features from radiographic medical pictures to reveal illness traits that are imperceptible to the human eye (50). An innovative study demonstrated the ability of AI to forecast gene changes in lung cancer using routine CT images, which could enable non-invasive genetic testing and individualized treatment strategies (50).

AI in MRI: AI has transformed prostate cancer treatment by enhancing the precision of mpMRI (51). AI helps differentiate between aggressive and non-aggressive forms of cancer by evaluating photos for malignancy-related patterns, which assists in determining treatment decisions. It is crucial to prevent unnecessary treatment of slow-growing tumors and to accurately focus treatment on fast-growing malignancies (51).

AI in CT Imaging: AI models are being created to improve the accuracy of CT scans for lung cancer detection (52). The algorithms can accurately detect tiny nodules and, when paired with the patient's clinical history, can forecast the probability of malignancy (52). This progress is particularly important for the early identification of lung cancer, as survival rates are strongly linked to the stage of diagnosis (52).

Clinical Impact and Implications: AI technology is advancing and is likely to grow more complex as it integrates with traditional imaging methods (48-52). It will play a larger role in improving diagnostic accuracy, tailoring treatments, and predicting outcomes in cancer care (52). This collaboration is expected to improve patient care, decrease delays in diagnosis, and perhaps result in substantial enhancements in cancer survival rates.

Table 4

Emerging Technologies in Radiology and Their Clinical Applications

Imaging Modality	Advantages	Disadvantages	Clinical Applications
Photon Counting Detector CT (PCD-CT) (53)	Higher spatial resolution, allowing for improved visualization of small anatomical structures and early detection of lesions. Reduced radiation dose compared to conventional CT scanners. Improved tissue contrast and material decomposition capabilities.	Limited availability and higher cost compared to conventional CT scanners. Longer acquisition times due to the need for multiple energy thresholds. Potential artifacts from photon counting technology, requiring optimization and validation.	Cardiovascular imaging for coronary artery evaluation and plaque characterization. Oncological imaging for detecting small tumors, assessing tumor vascularity, and evaluating treatment response. Bone imaging for identifying microfractures and assessing bone mineral density.
Quantitative Imaging Biomarkers (54)	Objective and reproducible measurements of tissue characteristics, aiding in disease diagnosis, prognosis, and treatment response assessment. Enables longitudinal monitoring of disease progression and treatment efficacy. Facilitates personalized treatment planning by identifying patients likely to benefit from specific therapies.	Standardization and validation of quantitative imaging biomarkers are ongoing challenges. Variability in imaging protocols and acquisition parameters may affect biomarker accuracy and reproducibility. Integration into clinical practice requires interdisciplinary collaboration and infrastructure support.	Cancer imaging for assessing tumor volume, density, and perfusion characteristics. Neurological imaging for quantifying brain tissue changes in neurodegenerative diseases and traumatic brain injury. Cardiovascular imaging for evaluating myocardial function, tissue viability, and coronary artery disease.
AI and Machine Learning in Radiology (52)	Automation of routine tasks such as image interpretation, segmentation, and lesion detection, leading to improved workflow efficiency and radiologist productivity. Enhanced diagnostic accuracy and consistency through integration of AI algorithms for image analysis and decision support. Predictive modeling and risk stratification for identifying high-risk patients and optimizing treatment strategies.	Limited interpretability and transparency of AI algorithms, posing challenges for clinical validation and regulatory approval. Data privacy and security concerns related to the use of patient health information for algorithm training and validation. Integration into existing clinical workflows may require substantial investment in infrastructure, training, and maintenance.	Oncological imaging for lesion detection, segmentation, and characterization, aiding in cancer diagnosis, staging, and treatment planning. Musculoskeletal imaging for fracture detection, joint disease assessment, and bone lesion characterization. Chest imaging for pulmonary nodule detection, lung cancer screening, and tuberculosis diagnosis.
3D Printing in Radiology (55)	Personalized anatomical models and surgical guides for preoperative planning and intraoperative navigation, reducing	Cost and time constraints associated with 3D printing processes, including equipment, materials, and labor.	Surgical planning and simulation in orthopedic, craniofacial, and maxillofacial surgeries. Oncological imaging for tumor

Health Nexus
E-ISSN: 2981-2569

	surgical time and improving surgical outcomes. Customized patient-specific implants and prosthetics for reconstruction following trauma, cancer resection, or congenital abnormalities. Training and education tools for medical professionals and patients, enhancing understanding of complex anatomical structures and pathologies.	Regulatory and quality assurance considerations for ensuring accuracy, reliability, and safety of printed models and devices. Limited evidence on long-term outcomes and cost-effectiveness compared to traditional approaches, warranting further research and validation.	visualization, margin assessment, and radiation therapy planning. Patient education and communication tools for explaining complex diagnoses and treatment options.

AI: Artificial Intelligence, CT: Computed Tomography

5. Collaboration Between Disciplines: Driving Innovation in Diagnostic Technologies

Interdisciplinary collaboration greatly speeds up the advancement of diagnostic technology, particularly in oncology (2). The interdependent interaction among radiologists, oncologists, computer scientists, and engineers is crucial for developing and applying sophisticated diagnostic technologies (2).

Radiologists and oncologists possess a profound comprehension of clinical requirements and the nuances of cancer diagnosis and therapy (2, 27, 37). Their views are crucial for identifying the issues that new technologies seek to address and for offering clinical validation of these improvements (27).

Computer scientists apply advanced computer methods such as AI and machine learning algorithms to enhance medical imaging (2, 27). Their skill is crucial for managing the large volumes of data produced by modern imaging technology and for creating software capable of learning from this data to recognize cancer-related trends (40, 42).

Engineers collaborate with radiologists and oncologists to create innovative imaging devices due to their expertise in developing and constructing advanced equipment (40). They play a crucial role in converting computational algorithms into practical applications, guaranteeing that these advancements are successful, trustworthy, and user-friendly in a healthcare environment (40).

This collaborative setting promotes an innovative culture that allows for overcoming the constraints of separate specialties (2, 27, 37). For instance, incorporating AI into imaging techniques, like creating AI-driven diagnostic programs for analyzing images, necessitates the smooth merging of these varied disciplines (42). Computer scientists require the clinical expertise of radiologists to efficiently train algorithms, while engineers assure the seamless integration of software with imaging gear (2). Moreover, this interdisciplinary method is crucial for understanding and maneuvering through the regulatory and ethical aspects of medical technology (27). Every field offers a distinct viewpoint that is essential for tackling the issues related to using new technology in clinical settings, including regulatory approval and ethical concerns in patient treatment (40). The advancement of diagnostic technology in cancer relies heavily on ongoing and improved collaboration within these fields (2). These individuals collaborate to drive technical innovation and ensure that these developments directly benefit cancer patients globally.

6. Challenges and Future Directions: Navigating the Landscape of Cancer Diagnostics

Progress in radiographic methods for cancer detection has difficulties across clinical, technological, and economic areas (55-57). From a clinical perspective, it is crucial to ensure that new diagnostic techniques enhance both accuracy and patient outcomes. This implies that new technologies need to be both sensitive and specialized, as well as accessible and actionable for patient care (3, 58, 59).

Clinical Challenges involve incorporating sophisticated diagnostic tools into established care protocols. These paths need to incorporate new technology like AI-driven tools, necessitating doctors to have faith and comprehension of novel data interpretation methods (3, 60). There is the continuous problem of ensuring that healthcare workers are taught and kept current with these rapid changes (3).

Technological Challenges involve the ongoing improvement and enhancement of diagnostic instruments. Innovation must be balanced with reliability, usability, and the capacity to incorporate new technologies into current healthcare systems (61, 62). Maintaining the operational efficiency and user-friendliness of diagnostic instruments becomes increasingly problematic as they get more complicated (61, 62).

E-ISSN: 2981-2569

7. Conclusion

This narrative review outlines the progress in radiographic modalities crucial for cancer detection, emphasizing a trend towards precision and personalization in oncological care. Advancing from traditional imaging to utilizing advanced techniques such as photon counting detector CT and multiparametric MRI significantly improves our diagnostic capabilities, allowing for more precise identification, characterization, and monitoring of malignancies. The main focus of this discussion is the thorough analysis of new diagnostic substances like contrast agents and radiotracers, which have significantly improved the accuracy and precision of existing imaging methods. These advancements aid in early tumor diagnosis and offer significant information on tumor physiology, improving treatment approaches and prognosis. The assessment also recognizes the significant difficulty of ensuring fair access to these sophisticated diagnostics worldwide. It promotes a focused initiative to remove obstacles to access, emphasizing the essential nature of global partnerships, legislative changes, and infrastructure funding in making healthcare innovation more accessible to all. The crucial importance of interdisciplinary collaboration in this technological growth is paramount. The collaboration of radiologists, oncologists, engineers, and computer scientists promotes an environment of innovation, essential for creating, testing, and ethically incorporating novel diagnostic technologies into clinical settings. This collaborative structure is crucial for both technological progress and for managing the regulatory and ethical challenges that come with using new technology in clinical settings. Advancements in imaging techniques, together with a more profound understanding of cancer at the molecular and genetic levels, are expected to significantly enhance oncological diagnostics. The shift towards more detailed and personalized diagnostic methods is crucial for boosting patient outcomes, improving the quality of life for cancer patients, and eventually, reaching the ambitious objectives of precision oncology.

Authors' Contributions

Z.A., A.H., and A.A. drafted the initial manuscript. All other authors reviewed, provided feedback, and approved the final version of the manuscript, in alignment with COPE's guidelines for authorship.

Declaration

In certain sections of our manuscript, we utilized the language model ChatGPT version 4.0 to assist in enhancing the academic writing (63-65).

Transparency Statement

Data are available for research purposes upon reasonable request to the corresponding author.

Acknowledgments

We would like to express our gratitude to all individuals helped us to do the project.

Declaration of Interest

The authors report no conflict of interest.

Funding

This research received no external funding.

Ethics Considerations

Not applicable.

References

1. World Health Organization. Cancer 2021 [Available from: https://www.who.int/news-room/fact-sheets/detail/cancer.
2. Ali Z, Hamdoun A. Comparative Analysis of Barium Enema and Computed Tomography Colonography: Diagnostic Performance, Patient Experience, and Healthcare Implications - A Narrative Review. New Asian Journal of Medicine. 2024;2(1):17-26. [DOI]
3. Fitzgerald RC, Antoniou AC, Fruk L, Rosenfeld N. The future of early cancer detection. Nature Medicine. 2022;28(4):666-77. [PMID: 35440720] [DOI]
4. Li M, Zhang Q, Yang K. Role of MRI-Based Functional Imaging in Improving the Therapeutic Index of Radiotherapy in Cancer Treatment. Frontiers in Oncology. 2021;11. [PMID: 26786412] [PMCID: PMC4846529] [DOI]
5. Hussain S, Mubeen I, Ullah N, Shah SSUD, Khan BA, Zahoor M, et al. Modern Diagnostic Imaging Technique Applications and Risk Factors in the Medical Field: A Review. BioMed Research International. 2022;2022:5164970. [PMID: 35707373] [PMCID: PMC9192206] [DOI]
6. Kowalewska B, Drozdz W, Kowalewski L. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) in autism research: literature review. Irish Journal of Psychological Medicine. 2022;39(3):272-86. [PMID: 33818321] [DOI]
7. Bruno F, Granata V, Cobianchi Bellisari F, Sgalambro F, Tommasino E, Palumbo P, et al. Advanced Magnetic Resonance Imaging (MRI) Techniques: Technical Principles and Applications in Nanomedicine. Cancers. 2022;14(7):1626. [PMID: 35406399] [PMCID: PMC8997011] [DOI]

Health Nexus
E-ISSN: 2981-2569

8. Sharma U, Jagannathan NR. Magnetic Resonance Imaging (MRI) and MR Spectroscopic Methods in Understanding Breast Cancer Biology and Metabolism. Metabolites. 2022;12(4):295. [PMID: 35448482] [PMCID: PMC9030399] [DOI]
9. Deantonio L, Castronovo F, Paone G, Treglia G, Zilli T. Metabolic Imaging for Radiation Therapy Treatment Planning: The Role of Hybrid PET/MR Imaging. Magnetic Resonance Imaging Clinics of North America. 2023;31(4):637-54. [PMID: 37741647] [DOI]
10. Hameed BMZ, Prerepa G, Patil V, Shekhar P, Zahid Raza S, Karimi H, et al. Engineering and clinical use of artificial intelligence (AI) with machine learning and data science advancements: radiology leading the way for future. Therapeutic Advances in Urology. 2021;13:17562872211044880. [PMID: 34567272] [PMCID: PMC8458681] [DOI]
11. Berenguer CV, Pereira F, Câmara JS, Pereira JAM. Underlying Features of Prostate Cancer—Statistics, Risk Factors, and Emerging Methods for Its Diagnosis. Current Oncology. 2023;30(2):2300-21. [PMID: 36826139] [PMCID: PMC9955741] [DOI]
12. Farshchi F, Hasanzadeh M. Microfluidic biosensing of circulating tumor cells (CTCs): Recent progress and challenges in efficient diagnosis of cancer. Biomedicine & Pharmacotherapy. 2021;134:111153. [PMID: 33360045] [DOI]
13. Lu L, Sun M, Lu Q, Wu T, Huang B. High energy X-ray radiation sensitive scintillating materials for medical imaging, cancer diagnosis and therapy. Nano Energy. 2021;79:105437. [DOI]
14. Yu K-H, Lee T-LM, Yen M-H, Kou SC, Rosen B, Chiang J-H, Kohane IS. Reproducible Machine Learning Methods for Lung Cancer Detection Using Computed Tomography Images: Algorithm Development and Validation. J Med Internet Res. 2020;22(8):e16709. [PMID: 32755895] [PMCID: PMC7439139] [DOI]
15. Singh M, Singh T, Soni S. Pre-operative Assessment of Ablation Margins for Variable Blood Perfusion Metrics in a Magnetic Resonance Imaging Based Complex Breast Tumour Anatomy: Simulation Paradigms in Thermal Therapies. Computer Methods and Programs in Biomedicine. 2021;198:105781. [PMID: 33065492] [DOI]
16. Rosati A, Gueli Alletti S, Capozzi VA, Mirandola M, Vargiu V, Fedele C, et al. Role of ultrasound in the detection of recurrent ovarian cancer: a review of the literature. Gland Surgery. 2020;9(4):1092-101. [PMID: 32953624] [PMCID: PMC7475345] [DOI]
17. van der Meulen NP, Strobel K, Lima TVM. New Radionuclides and Technological Advances in SPECT and PET Scanners. Cancers. 2021;13(24):6183. [PMID: 34944803] [PMCID: PMC8699425] [DOI]
18. Unterrainer M, Eze C, Ilhan H, Marschner S, Roengvoraphoj O, Schmidt-Hegemann NS, et al. Recent advances of PET imaging in clinical radiation oncology. Radiation Oncology. 2020;15(1):88. [PMID: 32317029] [PMCID: PMC7171749] [DOI]
19. Tanaka T, Yang M, Froemming AT, Bryce AH, Inai R, Kanazawa S, Kawashima A. Current Imaging Techniques for and Imaging Spectrum of Prostate Cancer Recurrence and Metastasis: A Pictorial Review. RadioGraphics. 2020;40(3):709-26. [PMID: 32196428] [DOI]
20. Kemp JA, Kwon YJ. Cancer nanotechnology: current status and perspectives. Nano Convergence. 2021;8(1):34. [PMID: 34727233] [PMCID: PMC8560887] [DOI]
21. Sechopoulos I, Teuwen J, Mann R. Artificial intelligence for breast cancer detection in mammography and digital breast tomosynthesis: State of the art. Seminars in Cancer Biology. 2021;72:214-25. [PMID: 32531273] [DOI]
22. Paudyal R, Shah AD, Akin O, Do RKG, Konar AS, Hatzoglou V, et al. Artificial Intelligence in CT and MR Imaging for Oncological Applications. Cancers. 2023;15(9):2573. [PMID: 37174039] [PMCID: PMC10177423] [DOI]
23. Akay S, Pollard JH, Saad Eddin A, Alatoum A, Kandemirli S, Gholamrezanezhad A, et al. PET/CT Imaging in Treatment Planning and Surveillance of Sinonasal Neoplasms. Cancers. 2023;15(15):3759. [PMID: 37568575] [PMCID: PMC10417627] [DOI]
24. Padhani AR, Koh D-M, Collins DJ. Whole-Body Diffusion-weighted MR Imaging in Cancer: Current Status and Research Directions. Radiology. 2011;261(3):700-18. [PMID: 22095994] [DOI]
25. Linet MS, Slovis TL, Miller DL, Kleinerman R, Lee C, Rajaraman P, Berrington de Gonzalez A. Cancer risks associated with external radiation from diagnostic imaging procedures. CA: A Cancer Journal for Clinicians. 2012;62(2):75-100. [PMID: 22307864] [PMCID: PMC3548988] [DOI]
26. Overcast WB, Davis KM, Ho CY, Hutchins GD, Green MA, Graner BD, Veronesi MC. Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors. Current Oncology Reports. 2021;23(3):34. [PMID: 33599882] [PMCID: PMC7892735] [DOI]
27. Torigian DA, Zaidi H, Kwee TC, Saboury B, Udupa JK, Cho Z-H, Alavi A. PET/MR Imaging: Technical Aspects and Potential Clinical Applications. Radiology. 2013;267(1):26-44. [PMID: 23525716] [DOI]
28. Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC, DiFilippo FP, et al. Single photon-emission computed tomography. Journal of Nuclear Cardiology. 2010;17(5):941-73. [PMID: 20552312] [DOI]
29. Giganti F, Allen C, Emberton M, Moore CM, Kasivisvanathan V. Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial. European Urology Oncology. 2020;3(5):615-9. [PMID: 32646850] [DOI]
30. Qiu J, Liu J, Bi Z, Sun X, Wang X, Zhang J, et al. Integrated slice-specific dynamic shimming diffusion weighted imaging (DWI) for rectal Cancer detection and characterization. Cancer Imaging. 2021;21(1):32. [PMID: 33827704] [PMCID: PMC8028796] [DOI]
31. Miles K, McQueen L, Ngai S, Law P. Evidence-based medicine and clinical fluorodeoxyglucose PET/MRI in oncology. Cancer Imaging. 2015;15(1):18. [PMID: 26578188] [PMCID: PMC4650106] [DOI]
32. Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. RadioGraphics. 2018;38(1):200-17. [PMID: 29320333] [DOI]
33. Savir-Baruch B, Schuster DM. Prostate Cancer Imaging with 18F-Fluciclovine. PET Clinics. 2022;17(4):607-20. [PMID: 36229104] [DOI]
34. Zhou Z, Lu Z-R. Gadolinium-based contrast agents for magnetic resonance cancer imaging. WIREs Nanomedicine and Nanobiotechnology. 2013;5(1):1-18. [PMID: 23047730] [PMCID: PMC3552562] [DOI]
35. Cutler CS, Lewis JS, Anderson CJ. Utilization of metabolic, transport and receptor-mediated processes to deliver agents for cancer diagnosis. Advanced Drug Delivery Reviews. 1999;37(1):189-211. [PMID: 10837735] [DOI]
36. Badea CT, Clark DP, Holbrook M, Srivastava M, Mowery Y, Ghaghada KB. Functional imaging of tumor

vasculature using iodine and gadolinium-based nanoparticle contrast agents: a comparison of spectral micro-CT using energy integrating and photon counting detectors. Physics in Medicine & Biology. 2019;64(6):065007. [PMID: 30708357] [PMCID: PMC6607440] [DOI]
37. Marcu LG, Moghaddasi L, Bezak E. Imaging of Tumor Characteristics and Molecular Pathways With PET: Developments Over the Last Decade Toward Personalized Cancer Therapy. International Journal of Radiation Oncology, Biology, Physics. 2018;102(4):1165-82. [PMID: 29907486] [DOI]
38. Granata V, Fusco R, Bicchierai G, Cozzi D, Grazzini G, Danti G, et al. Diagnostic protocols in oncology: workup and treatment planning. Part 1: the optimitation of CT protocol. European Review for Medical & Pharmacological Sciences. 2021;25(22).
39. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. Corrigendum to: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure European Heart Journal. 2012;34(2):158-. [PMID: 22611136] [PMCID: PMC4846529] [DOI]
40. Ghasemi M, Nabipour I, Omrani A, Alipour Z, Assadi M. Precision medicine and molecular imaging: new targeted approaches toward cancer therapeutic and diagnosis. American journal of nuclear medicine and molecular imaging. 2016;6(6):310.
41. Rudkouskaya A, Sinsuebphon N, Ochoa M, Chen S-J, Mazurkiewicz JE, Intes X, Barroso M. Multiplexed non-invasive tumor imaging of glucose metabolism and receptor-ligand engagement using dark quencher FRET acceptor. Theranostics. 2020;10(22):10309-25. [PMID: 32929350] [PMCID: PMC7481426] [DOI]
42. Rutman AM, Kuo MD. Radiogenomics: Creating a link between molecular diagnostics and diagnostic imaging. European Journal of Radiology. 2009;70(2):232-41. [PMID: 19303233] [DOI]
43. Ding Z, Wang N, Ji N, Chen Z-S. Proteomics technologies for cancer liquid biopsies. Molecular Cancer. 2022;21(1):53. [PMID: 35168611] [PMCID: PMC8845389] [DOI]
44. Do C, DeAguero J, Brearley A, Trejo X, Howard T, Escobar GP, Wagner B. Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolution. Kidney360. 2020;1(6):561-8. [PMID: 34423308] [PMCID: PMC8378745] [DOI]
45. Cosmai L, Porta C, Privitera C, Gesualdo L, Procopio G, Gori S, Laghi A. Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies. ESMO Open. 2020;5(2). [PMID: 32205339] [PMCID: PMC7204797] [DOI]
46. Rashidi A, Baratto L, Theruvath AJ, Greene EB, Jayapal P, Hawk KE, et al. Improved Detection of Bone Metastases in Children and Young Adults with Ferumoxytol-enhanced MRI. Radiology: Imaging Cancer. 2023;5(2):e220080. [PMID: 36999999] [PMCID: PMC10077085] [DOI]
47. Ravi H, Arias-Lorza AM, Costello JR, Han HS, Jeong DK, Klinz SG, et al. Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer. Radiology: Imaging Cancer. 2023;5(2):e220022. [PMID: 36734848] [PMCID: PMC10077095] [DOI]
48. He X, Liu X, Zuo F, Shi H, Jing J. Artificial intelligence-based multi-omics analysis fuels cancer precision medicine. Seminars in Cancer Biology. 2023;88:187-200. [PMID: 36596352] [DOI]
49. Gastounioti A, Desai S, Ahluwalia VS, Conant EF, Kontos D. Artificial intelligence in mammographic phenotyping of breast cancer risk: a narrative review. Breast Cancer Research. 2022;24(1):14. [PMID: 35184757] [PMCID: PMC8859891] [DOI]
50. Lecointre L, Dana J, Lodi M, Akladios C, Gallix B. Artificial intelligence-based radiomics models in endometrial cancer: A systematic review. European Journal of Surgical Oncology. 2021;47(11):2734-41. [PMID: 34183201] [DOI]
51. Sheth D, Giger ML. Artificial intelligence in the interpretation of breast cancer on MRI. Journal of Magnetic Resonance Imaging. 2020;51(5):1310-24. [PMID: 31343790] [DOI]
52. Qin Y, Deng Y, Jiang H, Hu N, Song B. Artificial Intelligence in the Imaging of Gastric Cancer: Current Applications and Future Direction. Frontiers in Oncology. 2021;11. [PMID: 34367946] [PMCID: PMC8335156] [DOI]
53. Yalon M, Sae-Kho T, Khanna A, Chang S, Andrist BR, Weber NM, et al. Staging of breast cancer in the breast and regional lymph nodes using contrast-enhanced photon-counting detector CT: accuracy and potential impact on patient management. British Journal of Radiology. 2023;97(1153):93-7. [PMID: 38263843] [DOI]
54. Obuchowski NA, Huang E, deSouza NM, Raunig D, Delfino J, Buckler A, et al. A Framework for Evaluating the Technical Performance of Multiparameter Quantitative Imaging Biomarkers (mp-QIBs). Academic Radiology. 2023;30(2):147-58. [PMID: 36180328] [PMCID: PMC9825639] [DOI]
55. Haleem A, Javaid M, Suman R, Singh RP. 3D printing applications for radiology: an overview. Indian Journal of Radiology and Imaging. 2021;31(01):010-7.
56. Vitzthum von Eckstaedt HV, Kitts AB, Swanson C, Hanley M, Krishnaraj A. Patient-centered Radiology Reporting for Lung Cancer Screening. Journal of Thoracic Imaging. 2020;35(2):85-90. [PMID: 31913258] [DOI]
57. Penedo FJ, Oswald LB, Kronenfeld JP, Garcia SF, Cella D, Yanez B. The increasing value of eHealth in the delivery of patient-centred cancer care. The Lancet Oncology. 2020;21(5):e240-e51. [PMID: 32359500] [DOI]
58. Suman BM, Christine MOB, Kevin B, Ryan CF, Julie AM, Samuel A. Repurposing Molecular Imaging and Sensing for Cancer Image–Guided Surgery. Journal of Nuclear Medicine. 2020;61(8):1113. [PMID: 32303598] [PMCID: PMC7413229] [DOI]
59. Cortes J, Perez-García JM, Llombart-Cussac A, Curigliano G, El Saghir NS, Cardoso F, et al. Enhancing global access to cancer medicines. CA: A Cancer Journal for Clinicians. 2020;70(2):105-24. [PMID: 32068901] [DOI]
60. Johnston K, Smith D, Preston R, Evans R, Carlisle K, Lengren J, et al. "From the technology came the idea": safe implementation and operation of a high quality teleradiology model increasing access to timely breast cancer assessment services for women in rural Australia. BMC Health Services Research. 2020;20(1):1103. [PMID: 33256724] [PMCID: PMC7708244] [DOI]
61. Mizuno K, Beltran H. Future directions for precision oncology in prostate cancer. The Prostate. 2022;82(S1):S86-S96. [PMID: 35657153] [PMCID: PMC9942493] [DOI]
62. Manickam P, Mariappan SA, Murugesan SM, Hansda S, Kaushik A, Shinde R, Thipperudraswamy SP. Artificial Intelligence (AI) and Internet of Medical Things (IoMT) Assisted Biomedical Systems for Intelligent Healthcare. Biosensors. 2022;12(8):562. [PMID: 35892459] [PMCID: PMC9330886] [DOI]
63. Dergaa I, Fekih-Romdhane F, Glenn JM, Fessi MS, Chamari K, Dhahbi W, et al. Moving Beyond the Stigma: Understanding and Overcoming the Resistance to the Acceptance and Adoption of Artificial Intelligence Chatbots. New Asian Journal of Medicine. 2023;1(2):29-36. [DOI]

64. Chtourou H, Guelmami N, Trabelsi K, Dergaa I. The Beginning of Our Journey: The Launch of the Tunisian Journal of Sports Science and Medicine. Tunisian Journal of Sports Science and Medicine. 2023;1(1):1-3. [DOI]

65. Dergaa I, Saad HB. Artificial Intelligence and Promoting Open Access in Academic Publishing Intelligence artificielle et promotion de l'accès libre dans la publication académique. La Tunisie medicale. 2023;101(06):533-6.

E-ISSN: 2981-2569